Announcements
- BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- BridgeBio Pharma Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
- BridgeBio Pharma to Participate in the 45th Annual Goldman Sachs Global Healthcare Conference
- BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia
- BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024
- Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma’s Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
- BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting
- BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024
- BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sensitivity Analysis of the Entire Study Population
More ▼
Key statistics
On Friday, BridgeBio Pharma Inc (2CL:FRA) closed at 25.21, 18.36% above the 52 week low of 21.30 set on Jun 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 24.47 |
---|---|
High | 25.21 |
Low | 24.47 |
Bid | 24.43 |
Offer | 24.92 |
Previous close | 24.50 |
Average volume | 243.00 |
---|---|
Shares outstanding | 187.13m |
Free float | 144.85m |
P/E (TTM) | -- |
Market cap | 5.06bn USD |
EPS (TTM) | -3.23 USD |
Data delayed at least 15 minutes, as of Jul 26 2024 15:00 BST.
More ▼